|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
3787890 |
| 003 |
ICU |
| 005 |
20030527212000.0 |
| 008 |
970611s1998 paua b 001 0 eng c |
| 010 |
|
|
|a 97025775
|
| 020 |
|
|
|a 1560532238 (alk. paper)
|
| 035 |
|
|
|a (NhCcYBP)YBT 97025775 //r98
|
| 035 |
|
|
|a (NhCcYBP)YBP99800020629
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d OrLoB-B
|d OCoLC
|
| 050 |
0 |
0 |
|a RC684.C34
|b C337 1998
|
| 060 |
1 |
0 |
|a QV 150 C14368 1997
|
| 082 |
0 |
0 |
|a 616.1/061
|2 21
|
| 245 |
0 |
0 |
|a Calcium antagonists in clinical medicine /
|c [edited by] Murray Epstein.
|
| 250 |
|
|
|a 2nd ed.
|
| 260 |
|
|
|a Philadelphia :
|b Hanley & Belfus,
|c c1998.
|
| 300 |
|
|
|a xviii, 590 p. :
|b ill. ;
|c 24 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|t Basic Principles.
|g 1.
|t Mechanisms of Action of Calcium Channel Antagonists /
|r David J. Triggle.
|g 2.
|t Abnormalities of Cardiovascular Calcium Metabolism Associated with Diabetes Mellitus and Metabolic Hypertension /
|r Amy Davidoff, Mary F. Walsh and James Marsh [et al.].
|g 3.
|t Pharmacokinetics of Calcium Antagonists: Implications for Therapy /
|r Henry L. Elliott, Peter A. Meredith and John L. Reid.
|g 4.
|t Endothelial Regulation of Vascular Tone and Growth: Role of Calcium Antagonists /
|r Rene R. Wenzel, Georg Noll and Thomas F. Luscher --
|t The Heart.
|g 5.
|t Cardiac Effects of Calcium Antagonists in Hypertension /
|r Franz H. Messerli and Leszek Michalewicz.
|g 6.
|t Calcium Antagonists and Myocardial Ischemia /
|r George W. Vetrovec.
|g 7.
|t Potential Usefulness of Calcium Antagonists in Ventricular Arrhythmias: Can Their Actions Be Targeted in Myocardial Ischemia? /
|r George E. Billman.
|g 8.
|t The Clinical Antiarrhythmic Effectiveness of Calcium Antagonists /
|r Simon Chakko and Arthur L. Bassett.
|g 9.
|t Are Calcium Antagonists Proarrhythmic? /
|r Arthur L. Bassett, Simon Chakko and Murray Epstein --
|t Hypertension.
|g 10.
|t Calcium Antagonists in the Management of Hypertension /
|r Murray Epstein.
|g 11.
|t Hemodynamic Effects of Calcium Antagonists in Hypertension /
|r Per Lund-Johansen.
|g 12.
|t Arterial Compliance and Effect of Calcium Antagonists /
|r Gerard M. London and Michel E. Safar.
|g 13.
|t Insulin and Glucoregulatory Hormones: Implications for Antihypertensive Therapy /
|r Dalila B. Corry and Michael L. Tuck --
|t Special Populations.
|g 14.
|t Diabetic Nephropathy: Focus on ACE Inhibition and Calcium Channel Blockade /
|r Murray Epstein and Mark E. Cooper.
|g 15.
|t Calcium Antagonists: Are They All Created Equal in Regard to Slowing Progression of Diabetic Nephropathy? /
|r Konstantinos Makrilakis and George L. Bakris.
|g 16.
|t Calcium Antagonists as Antihypertensive Agents in African-American Patients /
|r John M. Flack and Matthew R. Weir.
|g 17.
|t Calcium Antagonists in Elderly Patients with Systemic Hypertension /
|r Bryan Burns and William H. Frishman.
|g 18.
|t Management of High Blood Pressure in Pregnancy /
|r Ayub Akbari and Marshall D. Lindheimer.
|g 19.
|t Treatment of Perioperative Hypertension /
|r Jerrold H. Levy, Catherine Huraux and Margareta Nordlander --
|t Calcium Antagonists in the Treatment of Noncardiovascular Disorders.
|g 20.
|t Effects of Calcium Antagonists on Lipids /
|r Ronald B. Goldberg and Hermes Florez.
|g 21.
|t Calcium Antagonists and Central Nervous System Diseases /
|r Alexander Scriabine --
|t Calcium Antagonists and the Kidney.
|g 22.
|t Renal Hemodynamic Effects of Calcium Antagonists /
|r Koichi Hayashi, Takao Saruta and Murray Epstein.
|g 23.
|t Effects of Calcium Antagonists on Vasoactive Hormones /
|r Jose Tunon, Nieves Tarin and Jesus Egido.
|g 24.
|t Calcium Antagonists and the Kidney: Implications for Renal Protection /
|r Murray Epstein.
|g 25.
|t The Clinical Utility of Calcium Antagonists in Renal Transplant Recipients /
|r Matthew R. Weir --
|t Emerging Perspectives.
|g 26.
|t Fixed-dose Combination Therapy with Calcium Antagonists /
|r Murray Epstein and Bernard Waeber.
|g 27.
|t The Costs of Treating Hypertension /
|r William J. Elliott.
|g 28.
|t Dihydropyridine Calcium Antagonists and Sympathetic Activity: Relevance to Cardiovascular Morbidity and Mortality /
|r Frans H. H. Leenen.
|g 29.
|t Safety of Calcium Antagonists as Antihypertensive Agents: An Update /
|r Murray Epstein.
|
| 650 |
|
0 |
|a Calcium
|x Antagonists
|x Therapeutic use.
|
| 650 |
1 |
2 |
|a Calcium Channel Blockers
|x metabolism.
|
| 650 |
2 |
2 |
|a Calcium Channel Blockers
|x therapeutic use.
|
| 650 |
2 |
2 |
|a Heart Diseases
|x drug therapy.
|
| 650 |
|
7 |
|a Calcium
|x Antagonists
|x Therapeutic use.
|2 fast
|0 http://id.worldcat.org/fast/fst00844040
|
| 700 |
1 |
|
|a Epstein, Murray,
|d 1937-
|0 http://id.loc.gov/authorities/names/n82031881
|1 http://viaf.org/viaf/84874397
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 903 |
|
|
|a Hathi
|
| 035 |
|
|
|a (OCoLC)37180345
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 205b16ec-36f5-5525-9d9f-8a0dc6928264
|s d4f56fd0-9609-5e74-b2a3-8534718c1984
|
| 928 |
|
|
|t Library of Congress classification
|a RC684.C34 C337 1998
|l JCL
|c JCL-Sci
|i 4176339
|
| 927 |
|
|
|t Library of Congress classification
|a RC684.C34 C337 1998
|l JCL
|c JCL-Sci
|e VISI
|e CRERAR
|b 50679859
|i 6224519
|
